

### Investment Philosophy

We believe a portfolio of select large cap growth stocks may achieve above-benchmark long-term performance through capital appreciation, and by limiting downside risk.

### Investment Strategy

- Invests in large cap growth stocks we believe have superior appreciation potential, with an attractive combination of valuation, fundamental, earnings and technical characteristics.
- Utilizes proprietary, multi-factor, sector-specific models to rank stocks within each sector.
- Initial equal weight positions.
- Optimizes the portfolio to seek broad diversification across sectors, industries and individual companies, while controlling turnover.
- Utilizes proprietary risk screens to eliminate stocks we believe are likely to underperform.

### Product Highlights

- Quantitatively-based investment process with stringent risk controls.
- Integrates fundamental factors into proprietary quantitative models.
- Focuses on underperformance risk as much as outperformance opportunity.

### Fund Facts

Universe	Russell 1000 Growth Index
Benchmark	Russell 1000 Growth Index
Fund Inception	February 27, 2004
Expense Ratio	0.84%
Morningstar Large Cap Growth Category Average Expense Ratio	0.80%

### Assets Under Management as of 3/31/2023


Glenmede Quantitative U.S. Large Cap Growth Equity Portfolio	\$1.2 Billion
Glenmede Investment Management:	\$11.3 Billion

### Morningstar Rating

3/31/2023	Overall	3 Yr	5 Yr	10 Yr
GTLTX	★★★★★	★★★★★	★★★★	★★★★★
#Funds in Large Cap Growth Category	1138	1138	1052	809

Morningstar Ratings™ are based on risk-adjusted returns. The Overall Morningstar Rating™ is derived from a weighted average of the performance figures associated with a fund's 3-, 5-, and 10-year (if applicable) Morningstar Rating™ metrics.

### Investment Process



Fundamental Insights Driving Disciplined Decision-Making

### Performance (%) As of 3/31/2023

	QTD	YTD	1 Yr	3 Yr <sup>1</sup>	5 Yr <sup>1</sup>	10 Yr <sup>1</sup>	Since Incept <sup>1</sup>
GTLTX	9.18	9.18	-5.65	19.00	11.57	13.89	10.58
Russell 1000 Growth	14.37	14.37	-10.90	18.58	13.66	14.59	10.40
Excess Return	-5.19	-5.19	5.25	0.42	-2.09	-0.70	0.18

<sup>1</sup>Annualized returns. Inception date: 2/27/2004.

Performance data quoted represents past performance; past performance does not guarantee future results. The investment return and principal value of an investment will change so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance of the fund may be lower or higher than the performance quoted. Performance data current to the most recent month end may be obtained by calling 1.800.442.8299.

All figures based on monthly data as of 3/31/2023, unless otherwise noted.

## Fund Characteristics

	GTLTX	Russell 1000 Growth
Number of Holdings	65	509
Wtd Avg. Mkt Cap (\$B)	165.7	817.4
P/E	18.5	25.0
P/B	4.5	9.3
ROE	27.6	29.9
EPS Growth (5 yr)	26.8	24.9

## Sector Diversification (%)

	GTLTX	Russell 1000 Growth
Communication Services	8.20	7.14
Consumer Discretionary	12.99	14.34
Consumer Staples	7.19	5.99
Energy	1.93	1.36
Financials	5.26	6.72
Health Care	12.52	11.67
Industrials	8.88	8.16
Information Technology	39.26	41.79
Materials	2.24	1.31
Real Estate	1.23	1.46
Utilities	--	0.04
Cash	0.30	--

## Returns Based Statistics (vs Russell 1000 Growth Index)

	1 Yr	3 Yr	5 Yr	10 Yr
Information Ratio	0.73	0.05	-0.31	-0.14
Sharpe Ratio	-0.36	0.92	0.54	0.85
Tracking Error (%)	7.2	7.9	6.7	5.2
Std. Dev. (Portfolio) %	23.0	19.6	18.9	15.3
Std. Dev. (Index) %	26.5	22.7	20.8	16.5
Batting Average	0.67	0.53	0.48	0.49
Beta	0.84	0.81	0.86	0.89

Based on monthly data as of 3/31/2023. Standard deviation is annualized.

## Top Ten Holdings (%)

Arista Networks, Inc.	3.28
Synopsys, Inc.	3.07
Cadence Design Systems, Inc.	3.06
Warner Bros. Discovery, Inc. Series A	2.86
Regeneron Pharmaceuticals, Inc.	2.79
Amphenol Corporation Class A	2.79
CDW Corporation	2.73
Microsoft Corporation	2.62
ON Semiconductor Corporation	2.47
KLA Corporation	2.43
<b>Total</b>	<b>28.08</b>

## Management Team

**Vladimir de Vassal, CFA**  
Portfolio Manager

**Paul T. Sullivan, CFA**  
Portfolio Manager

**Alexander Atanasiu, CFA**  
Portfolio Manager

**David Marcucci, CFA**  
Research Analyst

**Jacob M. Adamcik, CFA**  
Research Analyst

**Ruohao Chen**  
Research Analyst

Holdings and sector allocations are subject to change and are not recommendations to buy or sell any security.

All figures based on monthly data as of 3/31/2023, unless otherwise noted.

The fund's investment objectives, risks, charges and expenses must be considered carefully before investing. The Glenmede Funds' prospectus contains this and other important information about the investment company, and it may be obtained by calling 1.800.442.8299, or visiting [www.glenmedeim.com](http://www.glenmedeim.com). Please read the prospectus carefully before you invest or send money. **Mutual fund investing involves risks; principal loss is possible. The Fund may invest in foreign securities which involve greater volatility and political, economic and currency risks and differences in accounting methods. The Fund may invest in IPOs and the market value of IPO shares could fluctuate considerably due to factors such as the absence of a prior public market, unseasoned trading, the small number of shares available for trading, and limited information about the issuer. Diversification does not assure profit, nor does it protect against loss in a declining market.** All returns are calculated in U.S. dollars. **Beta:** systematic risk of a portfolio; represents sensitivity to the benchmark. **Excess Return:** amount that returns exceed relative benchmark return. **Information Ratio:** ratio of expected return to risk, as measured by standard deviation. **Sharpe Ratio:** sharpe ratio is a simple measurement of the risk-adjusted performance. **Price to Book (P/B):** is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history, without adjustment for sales loads. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating™ for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating™ metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods. Each Morningstar category average represents a universe of funds with similar objectives. Morningstar ratings represented as unshaded stars are based on extended performance. These extended performance ratings are based on the historical adjusted returns prior to the inception date of the Institutional Class shares (Institutional Class inception was 11/05/2015) and reflect the historical performance of the oldest share class (inception date for Advisor Class shares was 2/27/2004), adjusted to reflect the fees and expenses of the Institutional Class shares. © 2018 Morningstar, Inc. All Rights Reserved. The information contained herein (1) is proprietary to Morningstar (2) may not be copied or distributed and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any sue of this information. **The Fund is distributed by Quasar Distributors, LLC.**